AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27914504
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with Simvastatin 40 mg/d (P/S)
Trial: 20105282
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of AQ and SP (AQ+SP)
Trial: 18086006
Drug: Sex steroid
RxNorm normalized name: Sex steroid binding globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sex steroid deficiency (‐T, ‐E)
Trial: 1347955
Drug: 2.4 mg
RxNorm normalized name: pectin 2.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.4 mg FTC nicotine cigarettes
Trial: 1347955
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg FTC nicotine cigarettes
Trial: 3920770
Drug: Cimetidine 300
RxNorm normalized name: cimetidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 300 mg 4 times a day
Trial: 3920770
Drug: Misoprostol high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol high-dose (200 micrograms 4 times a day)
Trial: 30486574
Drug: Dexmedetomidine (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (loading dosage 0.5 μg/kg, continuous infusion 0.2 μg·kg(‐1)·h(‐1) until 30 minutes before the end of operation)
Trial: 27272161
Drug: Fluticasone 125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone 125 μg + formoterol 5 μg in the same device
Trial: 27272161
Drug: Fluticasone 125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone 125 μg + formoterol 12 μg as needed
Trial: 27272161
Drug: Fluticasone 250
RxNorm normalized name: FLUTICASONE 250MCG/BLSTR PO INH ROTADISK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone 250 μg + formoterol 12 μg as needed
Trial: 20035039
Drug: Levofloxacin (LVFX)
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin (LVFX) 500 mg single oral dose
Trial: 15853102
Drug: Rotating rubber
RxNorm normalized name: Aspergillus ruber
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotating rubber cup with prophylaxis gel (PG)
Trial: 7485938
Drug: Spinal anaesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal anaesthesia and midazolam (0.05 mg/kg)
Trial: 2249377
Drug: Adinazolam mesylate
RxNorm normalized name: mesylate
DrugBank: Adinazolam (DB00546)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adinazolam mesylate (10, 30, 50 mg)
Trial: 2249377
Drug: NDMAD mesylate
RxNorm normalized name: mesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NDMAD mesylate (10, 30, 50 mg)
Trial: 30621746
Drug: Reduced-dose TNF
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Reduced-dose TNF inhibitors (approximately half of the full dose)
Trial: 27702622
Drug: DSAEK with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DSAEK with active air infusion system
Trial: 27702622
Drug: DSAEK without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DSAEK without active air infusion system
Trial: 26445094
Drug: nab-paclitaxel (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nab-paclitaxel (125 mg/m²) plus gemcitabine (1000 mg/m²) given on days 1, 8, and 15 every 28 days
Trial: 26445094
Drug: nab-paclitaxel (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nab-paclitaxel (125 mg/m²) plus sLV5FU2 (leucovorin 400 mg/m² followed by bolus 400 mg/m² 5-fluorouracil and by 5-fluorouracil 2400 mg/m² as an 46-h intravenous infusion) given on days 1 and 15 every 28 days
Trial: 23825656
Drug: Condition A
RxNorm normalized name: CONDITION AND ENHANCE SYSTEM TRAVEL-SIZE SURGICAL KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Condition A (continuous transdermal alcohol monitoring anklet, no alcohol consumption for 14 days)
Trial: 20670293
Drug: Tigecycline (TGC)
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tigecycline (TGC) 100 mg initial dose followed by 50 mg every 12 h
Trial: 20670293
Drug: Ceftriaxone (CTX)
DrugBank: Ceftriaxone (DB01212)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (CTX) 2 g once daily plus Metronidazole (MET) 1-2 g daily
Trial: 12811360
Drug: Methotrexate (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (low dose, 6 oral doses of 30 mg/m2; high dose, 1 g/m2 intravenously) followed by intravenous mercaptopurine (1 g/m2 over a 6-hour period)
Trial: 12811360
Drug: Mercaptopurine alone
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mercaptopurine alone (1 g/m2 over a 6-hour period)
Trial: 1893906
Drug: 3 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg.kg‐1 body weight of caffeine (C3)
Trial: 1893906
Drug: 5 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg.kg‐1 body weight of caffeine (C5)
Trial: 1893906
Drug: gelatin capsule
RxNorm normalized name: Gelatin Capsules
DrugBank: Gelatin (DB11242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gelatin capsule (C)
Trial: 1893906
Drug: C3 and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C3 and C5 treatments
Trial: 29391380
Drug: Protein-enriched, milk-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein-enriched, milk-based supplements (27.5 g whey protein/day)
Trial: 29391380
Drug: Isoenergetic placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoenergetic placebo products (<1.5 g protein/day)
Trial: 27590454
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser treatment at auriculotherapy points
Trial: 23935745
Drug: Porcine acellular
RxNorm normalized name: porcine acellular small intestine submucosa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Porcine acellular dermal xenograft (ADX) in combination with autologous split‐thickness skin grafting
Trial: 18495806
Drug: Valproate (Depakine‐Chrono)
RxNorm normalized name: valproate
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproate (Depakine‐Chrono) 3000 mg/day
Trial: 17168254
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of lithium and T3
Trial: 8996846
Drug: i.v. infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. infusion of adrenaline (1 microgram/min)
Trial: 8996846
Drug: i.v. infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. infusion of isoprenaline (1 microgram/min)
Trial: 8996846
Drug: i.v. infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. infusion of isoprenaline (1 microgram/min) with pretreatment with 100 mg talinolol
Trial: 8996846
Drug: p.o. administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: p.o. administration of 1200 mg celiprolol
Trial: 8996846
Drug: p.o. administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: p.o. administration of 0.4 mg bimakalim
Trial: 8996846
Drug: p.o. administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: p.o. administration of PDE-III inhibitors meribendan and isomazole
Trial: 2088025
Drug: Oral etretinate
RxNorm normalized name: etretinate
DrugBank: Etretinate (DB00926)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral etretinate
Trial: 29095358
Drug: Oral spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral spironolactone treatment
Trial: 29984418
Drug: Unguided internet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unguided internet cognitive-behavioral treatment (ICBT) for perfectionism
Trial: 26242288
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg menthol
Trial: 26242288
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg nicotine + 30 mg menthol
Trial: 12937858
Drug: Oral suspension
RxNorm normalized name: Oral Suspension
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral suspension of megestrol acetate (MA) at a daily dose of 480-840 mg
Trial: 12937858
Drug: Oral suspension
RxNorm normalized name: Oral Suspension
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral suspension of megestrol acetate (MA)
Trial: 11732527
Drug: Placebo (Intralipid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Intralipid 1 ml h(‐1))
Trial: 3066417
Drug: Sublingual lorazepam
RxNorm normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual lorazepam
Trial: 6136288
Drug: Intramuscular (i.m.)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (i.m.) lorazepam
Trial: 30401369
Drug: Opsite combined
RxNorm normalized name: DRESSING,OPSITE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opsite combined with wet gauze and eye ointment (ointment group)
Trial: 24444360
Drug: Umbilical vein
RxNorm normalized name: Sus scrofa vein preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Umbilical vein injection of 800 mcg misoprostol dissolved in 20 mL of normal saline
Trial: 24444360
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving 20 mL of normal saline
Trial: 17711616
Drug: Current asthma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current asthma therapy (control)
Trial: 15966467
Drug: Glimepiride/Specifar (test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride/Specifar (test preparation)
Trial: 12472990
Drug: Local antibiotic
RxNorm normalized name: RECTAL,LOCAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local antibiotic therapy combined with scaling and root planing
Trial: 8589139
Drug: Intravenous Immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Immunoglobulin (IVIG) prophylaxis
Trial: 31628486
Drug: COMBO (continuing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COMBO (continuing csDMARD therapy)
Trial: 31628486
Drug: MONO (withdrawing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MONO (withdrawing csDMARD therapy)
Trial: 19474512
Drug: R-CHOP therapy
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-CHOP therapy (rituximab combined with cyclophosphamide, doxorubicin, vincristine, and predonisolone)
Trial: 17265094
Drug: HES preload
RxNorm normalized name: HE-2200
DrugBank: HE-2200 (DB06257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HES preload group (15 ml x kg(‐1) before spinal anesthesia, n = 18)
Trial: 17265094
Drug: HES coload
RxNorm normalized name: HE-2200
DrugBank: HE-2200 (DB06257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HES coload group (15 ml x kg(‐1) after induction of spinal anesthesia, n = 18)
Trial: 17265094
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no rapid infusion, n = 18)
Trial: 11739069
Drug: Bupropion sustained-release
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion sustained-release (100 mg-300 mg/day)
Trial: 11739069
Drug: Paroxetine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (10 mg-40 mg/day)
Trial: 10195027
Drug: Patient Delivered
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient Delivered Partner Medication (PDPM)
Trial: 7842362
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 200 micrograms aqueous nasal spray twice daily
Trial: 7842362
Drug: Matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo spray
Trial: 3170392
Drug: Single daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single daily dose of netilmicin plus metronidazole
Trial: 3170392
Drug: Thrice daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice daily dose of netilmicin plus metronidazole
Trial: 24737406
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment group (UPPP + Oral Appliance)
Trial: 23161360
Drug: 3 ml
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 ml ropivacaine 0.75% plus 20 µg dexmedetomidine (RpD)
Trial: 23161360
Drug: 3 ml
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 ml ropivacaine 0.75% (R)
Trial: 23161360
Drug: 3 ml
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 ml ropivacaine 0.75% plus systemic 20 µg dexmedetomidine (RsD)
Trial: 21574873
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of l-arginine (0.075 g·kg(‐1) of body mass)
Trial: 21574873
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of l-arginine (0.15 g·kg(‐1) of body mass)
Trial: 21574873
Drug: Low and
RxNorm normalized name: ZINC OXIDE 88 mg in 1 mL TOPICAL LOTION [Ciele Glow and Protect]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low and High dose of l-arginine
Trial: 17027233
Drug: Konjac glucomannan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Konjac glucomannan (KGM) 1.5 g/meal, 4.5 g/d for 21 days
Trial: 15617456
Drug: telmisartan 40
RxNorm normalized name: telmisartan 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: telmisartan 40 mg once daily
Trial: 9928753
Drug: enalapril 10
RxNorm normalized name: enalapril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enalapril 10 mg once daily
Trial: 8328575
Drug: Triazolam plus
RxNorm normalized name: Triazolam
DrugBank: Triazolam (DB00897)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triazolam plus behavioral therapy
Trial: 3016071
Drug: Control (NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (NaCl infusion study)
Trial: 31640921
Drug: Platelet-rich plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-rich plasma (PRP) therapy
Trial: 22527984
Drug: Folate <5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Folate <5 ug/L
Trial: 22527984
Drug: 25‐hydroxy vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25‐hydroxy vitamin D <20 ng/mL
Trial: 21275160
Drug: Chinese medicine
RxNorm normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese medicine and general stroke-treatment (135 patients)
Trial: 21275160
Drug: General stroke-treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General stroke-treatment only (126 patients)
Trial: 18848094
Drug: Propofol (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (administered by OMS)
Trial: 18848094
Drug: Propofol (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (administered by non-OMS)
Trial: 16096449
Drug: 0.2% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% chlorhexidine gel, three times a day during the entire ICU stay
Trial: 16096449
Drug: Placebo gel,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel, three times a day during the entire ICU stay
Trial: 12045487
Drug: Tenofovir DF
RxNorm normalized name: LAMIVUDINE 300MG/TENOFOVIR DF 300MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenofovir DF 300 mg once-daily
Trial: 12045487
Drug: Tenofovir DF
RxNorm normalized name: LAMIVUDINE 300MG/TENOFOVIR DF 300MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenofovir DF 300 mg therapy
Trial: 1326582
Drug: Intranasal interferon‐alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal interferon‐alpha 2b, ipratropium, and oral naproxen; treatment started 24 hours after inoculation, continued three times a day for 4 days
Trial: 29676237
Drug: Ultramicronized palmitoylethanolamide
RxNorm normalized name: Palmitoylethanolamide
DrugBank: Palmidrol (DB14043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultramicronized palmitoylethanolamide (600 mg twice daily)
Trial: 29676237
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment except surgical therapy)
Trial: 12878631
Drug: Oxygen 50%
RxNorm normalized name: Nitrous oxide 50% and oxygen 50% gas for inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen 50% administration during surgery and for 2 h post-surgery
Trial: 12878631
Drug: Oxygen 30%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen 30% administration during surgery and for 2 h post-surgery
Trial: 12878631
Drug: Oxygen 50%
RxNorm normalized name: Nitrous oxide 50% and oxygen 50% gas for inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen 50% administration
Trial: 12878631
Drug: Oxygen 30%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen 30% administration
Trial: 10388309
Drug: 100 ml
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml of contrast material (iopamidol 300 mgI/ml)
Trial: 10388309
Drug: 50 ml
RxNorm normalized name: TPN Bag 250 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 ml of contrast material (iopamidol 300 mgI/ml)
Trial: 30796194
Drug: Zoledronate (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zoledronate (10 courses of 4 mg intravenous infusions)
Trial: 29043927
Drug: Novel proprietary
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel proprietary curcumin liquid droplet micromicellar formulation (CLDM), 400 mg dose, containing 64.6 mg curcumin
Trial: 29043927
Drug: 95% curcumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 95% curcumin powder in capsule form, 400 mg dose, containing 323 mg curcumin
Trial: 27692279
Drug: Intravenous normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous normal saline infusion as a bolus of 22 ml/kg body weight (approximately 2 L)
Trial: 27692279
Drug: Control: intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control: intravenous normal saline infusion at a minimal rate to keep the vein open
Trial: 25148841
Drug: Date palm
RxNorm normalized name: date palm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Date palm pollen (DPP) administered orally (2 g daily for 42 days)
Trial: 10815850
Drug: Experimental bicarbonate
RxNorm normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental bicarbonate solution
Trial: 8751396
Drug: Conformal neutron/photon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conformal neutron/photon irradiation with neoadjuvant hormonal therapy
Trial: 8751396
Drug: Conformal neutron/photon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conformal neutron/photon irradiation without neoadjuvant hormonal therapy
Trial: 29902979
Drug: 5% imiquimod
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% imiquimod cream, applied intravaginally three times a week for 16 weeks.
Trial: 29902979
Drug: Large Loop
RxNorm normalized name: Bos taurus large intestine preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large Loop Excision of the Transformation Zone (LLETZ) treatment, performed according to current guidelines.
Trial: 26841373
Drug: Single intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intramuscular injection of 0.03 mg rhTSH
Trial: 23015069
Drug: Fixed dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose approach (3 mg/day)
Trial: 17655682
Drug: Desmopressin MELT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin MELT (sublingual lyophilisate)
Trial: 17655682
Drug: Tablet formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet formulation of desmopressin
Trial: 12665498
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg micronized fenofibrate daily
Trial: 1906160
Drug: Cefprozil (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefprozil (30 mg/kg/day divided into two equal doses)
Trial: 1906160
Drug: Amoxicillin clavulanate
RxNorm normalized name: amoxicillin / clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin clavulanate potassium (40 mg/kg/day divided into three equal doses)
Trial: 1906160
Drug: Amoxicillin clavulanate
RxNorm normalized name: amoxicillin / clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin clavulanate potassium
Trial: 6137601
Drug: Aldose reductase
RxNorm normalized name: Aldose reductase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aldose reductase inhibitor ('Sorbinil'‐‐Pfizer CP 45, 634)
Trial: 23052819
Drug: Abduction splint
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abduction splint treatment compliance
Trial: 15816472
Drug: Antioxidant biofactor
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant biofactor AOB (3x2 sachets of 3 g powder each for 3 months)